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ABSTRACT
Objectives To investigate the cost-effectiveness of a 
telehealthcare solution in addition to usual care compared 
with usual care.
Design A 12-month cost-utility analysis conducted 
alongside a cluster-randomised trial.
Setting Community-based setting in the geographical 
area of North Denmark Region in Denmark.
Participants 26 municipality districts define 
randomisation clusters with 13 districts in each arm. 
1225 patients with chronic obstructive pulmonary disease 
were enrolled, of which 578 patients were randomised to 
telehealthcare and 647 to usual care.
Interventions In addition to usual care, patients in 
the intervention group received a set of telehealthcare 
equipment and were monitored by a municipality-based 
healthcare team. Patients in the control group received 
usual care.
Main outcome measure Incremental costs per quality-
adjusted life-years gained from baseline up to 12 months 
follow-up.
Results From a healthcare and social sector 
perspective, the adjusted mean difference in total costs 
between telehealthcare and usual care was €728 (95% 
CI −754 to 2211) and the adjusted mean difference 
in quality-adjusted life-years gained was 0.0132 
(95% CI −0.0083 to 0.0346). The incremental cost-
effectiveness ratio was €55 327 per quality-adjusted 
life-year gained. Decision-makers should be willing 
to pay more than €55 000 to achieve a probability of 
cost-effectiveness >50%. This conclusion is robust 
to changes in the definition of hospital contacts and 
reduced intervention costs. Only in the most optimistic 
scenario combining the effects of all sensitivity analyses, 
does the incremental cost-effectiveness ratio fall below 
the UK thresholds values (€21 068 per quality-adjusted 
life-year).
Conclusions Telehealthcare is unlikely to be a cost-
effective addition to usual care, if it is offered to all 
patients with chronic obstructive pulmonary disease 
and if the willingness-to-pay threshold values from the 
National Institute for Health and Care Excellence are 
applied.
Trial registration  Clinicaltrials. gov, NCT01984840, 14 
November 2013.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is a progressive lung disease.1 The 
main symptoms of COPD are dyspnoea, 
recurrent lung infections, abnormal sputum, 
wheezing, decreased exercise tolerance 
and ‘smoker’s cough’.2 Depending on the 
severity of COPD, patients can experience a 
number of exacerbations, where symptoms 
become more severe than normal, which are 
often associated with a further progression 
of the disease2 and anxiety.3 COPD is one 
of the most prevalent and deadly diseases in 
the world.4 The global prevalence of COPD 
is high (11.7%).5 COPD is associated with 
high mortality,6 presence of comorbidities7 8 
and reduced health-related quality of life.9 10 
COPD poses a substantial financial burden on 
healthcare systems, for example, the annual 
direct costs for COPD has been estimated 
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Research
Strengths and limitations of this study
 ► This study reports the within-trial cost-effectiveness 
of a pragmatic large-scale asynchronous 
telehealthcare initiative in order to improve the 
international evidence base of the economic 
effects of telehealthcare for patients with chronic 
obstructive pulmonary disease.
 ► A relatively broad healthcare and social sector 
perspective was chosen and the cost  analyses of 
resource use are based on register data.
 ► A limitation of the study is that only 61% of the 
participants had complete registrations of all 
cost categories and outcomes.
 ► The way telehealthcare was implemented may 
have affected cost-effectiveness, since the 
involved organisations and healthcare professionals 
underwent a steep learning curve after 
implementation of the telehealthcare solution, where 
they had to find new ways of working together and 
adapt to new work procedures.
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to be  US$20–26 billion in the USA with hospital admis-
sions representing 52%–70% of all direct costs.11 A recent 
Danish study has estimated that COPD is responsible for 
8300 years of life lost and €174 million in annual direct 
cost for treatment and care.12
Telehealthcare has been suggested as a possible 
effective intervention to patients with COPD on espe-
cially health-related quality of life.13 Telehealthcare is 
a technology that contains data from a patient which is 
transferred electronically over a physical distance and 
healthcare professionals exercise their judgement in 
providing personalised feedback to the patient based 
on these data.14 Some feasibility studies including 
cost analyses have previously suggested an added value of 
telehealthcare compared with usual practise and some of 
these studies show that telehealthcare may lower hospital 
or healthcare costs.15–19 But most recent systematic 
reviews have questioned the quality of this evidence and 
have requested more cost-effectiveness evaluations,20–24 
preferably with broader cost-perspectives.25
The objective of this paper is to add to this international 
evidence base on the cost-effectiveness of telehealthcare 
by presenting the results of a cost-utility analysis of a tele-
healthcare intervention to patients with COPD compared 
with usual practise. The analysis was nested within a 
12-month cluster-randomised trial (called ‘TeleCare 
North’) that were conducted in the geographic area of 
North Denmark Region in Denmark from 2013 to 2014.
METHODS
A more detailed trial protocol has been published else-
where,26 but a brief summary is provided in table 1. 
Twenty-six municipality districts in North Denmark 
Region define the randomisation clusters with 13 districts 
in each arm. In addition to usual care, patients in the inter-
vention group received a set of telehealthcare equipment 
and were monitored by a community-based healthcare 
team. Patients in the control received usual care.
The primary outcome measure for the cost-effective-
ness analysis was the incremental cost-effectiveness ratio 
(ICER) expressed as the total cost per quality-adjusted 
life-year (QALY) gained measured from baseline to 
follow-up at 12 months. In defining the total costs, this 
trial adopted a healthcare and social care sector perspec-
tive (including hospital services, primary care, medicine, 
home care services and rehabilitation).
Healthcare service use and healthcare costs
Healthcare and social care service use were all esti-
mated based on register data by applying a unique civil 
registration number that all Danish citizens have and 
that makes precise linkage between registers possible. 
National patient-level data for all hospital contacts were 
collected from the Danish National Patient Register,27 
which contains all inpatient, outpatient and emergency 
ward visits in Denmark. The total costs for each contact 
is a variable in these datasets and are valued based on the 
diagnose-related group, the actual procedures conducted 
and the duration of the contact.28 The included admis-
sions, outpatient and emergency ward visits were in the 
main analysis restricted to those defined as COPD-specific 
in the Danish Register for COPD.29
All contacts between patients and the primary care 
sector were collected from the National Health Insurance 
Service Register.30 The costs for each contact is part of 
the dataset and are valued based on fees negotiated in 
a collective agreement.31 At present, it is not possible to 
identify the cause of contact to the primary care sector, so 
all contacts are included.
Medication use was taken from The Danish Register 
of Medicinal Product Statistics that contains informa-
tion about what prescribed medicine citizens purchase 
in Denmark.32 For this analysis, these are restricted to 
patient-level medicine associated with COPD (R03 ATC 
codes), specific antibiotics, antifungals and medicine for 
anxiety, all associated with the treatment of COPD exac-
erbations, as well as medicine for smoking cessation. The 
costs for each product is given in this dataset and is valued 
based on a standardised pharmacy consumer price.33
Patient-level community care service use was collected 
from individual care systems in each of the 26 included 
municipality districts. The type and duration of standard 
care activities such as personal care, practical help, home 
nursing care and rehabilitation activities are routinely 
recorded for each contact. Each municipality district 
values contacts differently based on an internal calculated 
mean hourly cost. It was pragmatically decided to value 
time consumption in municipality districts as an average 
of the reported hourly costs from municipality districts. 
Four of the 26 municipality districts in the trial were 
implementing a different information technology (IT) 
system at the time of data collection, which meant that 
rehabilitation costs for these four municipality districts 
were unavailable (2 municipality districts in the tele-
healthcare group and 2 in the usual care group).
Healthcare service use was collected for 12 months to 
allow for within-trial costs to be calculated. In addition, 
patient-level health service use was also collected 12 
months prior to randomisation, because it was suspected 
that baseline differences in costs could occur that would 
not be explained by differences in health status or socio-
demographic characteristics by patients, for example, 
due to variations in referral and visitation practises across 
municipality districts.
Intervention costs
Costs associated only with the clinical trial, preparing the 
organisation and developing the telehealthcare solution 
were excluded. Intervention costs were costs of hardware 
and peripherals, installation and deinstallation costs, 
maintenance and support costs, training costs for health-
care professionals, patient-specific training, monitoring 
costs and project management costs.
Per person costs of the ‘package’ of telehealthcare 
equipment (the so-called ‘Telekits’ consisting of a tablet 
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and peripherals) were calculated. The ‘Telekits’ supplied 
were exactly the same for all patients and was purchased 
to each patient ahead of the trial and valued as prices 
paid. The per person costs of installation/deinstallation 
and swopping any defects in the equipment was negoti-
ated with an external supplier prior to the trial and valued 
as prices paid. Per patient maintenance and support costs 
consisted of software licenses and data charges, technical 
support to patients and healthcare professionals as well 
as IT infrastructure and application maintenance and 
valued as prices paid. Costs associated with IT infrastruc-
ture  and application maintenance was not dependent 
on the number of patients in the trial but the software 
and hardware configuration employed by the telehealth-
care solution which in principle could include all patients 
with COPD and patients with chronic heart failure. It was 
decided to allocate these costs on the estimated number 
of patients with COPD and chronic heart failure in North 
Denmark Region (10 500 patients).34 35 The per patient 
costs of training healthcare professionals were based on 
planned time spent conducting education workshops 
in COPD disease awareness and the telehealthcare 
solution, the number of conducted workshops and the 
average hourly wage for a community district nurse. Per 
Table 1 Description of the Danish TeleCare North cluster-randomised trial
Eligible criteria for 
clusters
All municipalities in North Denmark Region except one (a small island off the coast), 10 municipalities 
in all. Each municipality consisted of between 2 and 5 municipality districts and these districts were 
randomisation units, 26 municipality districts in total (13 in each arm).
Eligible criteria for 
patients
COPD as primary disease, diagnosis by spirometry, in treatment according to guidelines recommended 
by ‘The Global Initiative for Chronic Obstructive Lung Disease’,1 at least two exacerbations within the 
past 12 months, motivated for treatment, fixed residence in North Denmark Region, The Modified Medical 
Research Council scale (mMRC)≥2 or mMRC≥3 and COPD Assessment Test≥10. Exclusion criteria were: no 
phone line or Global System for Mobile communications coverage, unable to understand Danish sufficiently 
to complete the study questionnaires or diagnosed with a cognitive impairment
Intervention 
group: cluster-
level intervention
Municipality district healthcare personnel (primarily nurses and health assistants) were trained in two 
separate sessions. One session focused on the technical aspects of the tablet and physical measurements. 
Another session focuses on general disease awareness and communication with patients. The training 
was performed by members of the trial administration office. General practitioners were responsible for 
establishing threshold values for physical measurements. Nurses in the patient’s residing municipality 
were responsible for monitoring the data obtained and should incorporate monitoring time duties with their 
existing job responsibilities. Exemptions were patients with COPD receiving oxygen therapy and patients 
with COPD with open hospital admissions who were monitored at their hospital as usual. Patients were 
monitored asynchronously by a nurse on a daily basis. Measurements were classified with either a green, 
yellow or red code (green code: no threshold values were exceeded; yellow code: one or more values 
exceeded the threshold values; red code: one or more values exceeded the threshold values and had not 
previously been recorded). The nurse had the option to contact the patient by telephone and/or the patient’s 
general practitioner and/or dispatch an ambulance. Installation, swopping of defects, deinstallation and 
technical support and maintenance of the equipment was handled by information technology specialists
Intervention 
group: patient-
level intervention
Telephone contact to each patient from municipality healthcare personnel no later than 10 days after 
randomisation, and a 45 min appointment scheduled for patients who wanted to receive the tablet at home. 
For those who wished to receive the tablet at a municipality health centre, a 75 min appointment was 
scheduled with 3–4 patients in each group. At both appointments, a nurse from the patients’ municipalities 
demonstrated the use of the tablet and instructed patients in how to conduct physical measurement. 
Patients were asked to measure their vital signs daily during the first 2 weeks (both weekdays and 
weekends) and 1–2 times weekly after the first 2 weeks. A 45 min follow-up visit was scheduled 3–4 weeks 
after the first appointment to check if the patient used the device appropriately and if the threshold values 
of the physical measurements needed to be adjusted
Intervention 
group: device
All patients received the same device and peripherals. It consisted of a standard tablet (Samsung Galaxy) 
containing information on handling COPD in general and software (two apps) that automatically instructs 
the patient in handling COPD during exacerbations. The tablet can collect and wirelessly transmit data on 
blood pressure, pulse, blood oxygen saturation and weight via an attached Fingertip Pulse Oximeter, a 
digital blood pressure monitor, and a scale
Control group: 
usual care
Usual practise for caring for patients with COPD is the responsibility of the patient’s general practitioner 
(treatment and monitoring) and the municipalities (practical help and home nursing care). Patients with 
COPD can make appointments with their general practitioner or call the emergency contact number without 
copayment in order to get treatment or advice in managing COPD, but this advice is not personalised. 
Community care administered by municipality district personnel comes at regular intervals based on a 
clinically based estimate of the patients’ needs, but these personnel are not necessarily certified nurses and 
often not fully educated in COPD and not on call
COPD, chronic obstructive pulmonary disease.
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patient costs of patient-specific training were based on 
planned time and valued based on a mean hourly wage 
for a community district nurse. Time spent per patient 
on monitoring were estimated by time registries in 
the municipality districts and valued based on a mean 
hourly wage for a community district nurse. Based on 
the experiences gained with the implementation in the 
trial period, it was estimated that it would be necessary 
to have an administrative officer employed to ‘run’ the 
telehealthcare solution, should it be implemented in 
routine practise (coordinating activities, contract super-
vision, etc). Project management costs were valued as 
mean yearly salary for an administrative officer including 
all standardly available pensions and pay supplements.36 
As with IT infrastructure and application maintenance, 
these costs could be allocated on more patients than in 
the trial and they were therefore also allocated on the esti-
mated number of patients with COPD and chronic heart 
failure in North Denmark Region (10 500 patients).34 35
Equipment costs (the Telekits), installation/deinstallation 
costs, costs associated with training healthcare profes-
sionals and patient-specific training were annuitised over 
a period of 5 years with a discount rate of 3% per annum 
and presented as equivalent annual cost. Five years and 3% 
can be used as standard lifetime and discount rate for ‘other 
IT equipment’ in Danish capital accounting.37
All costs are reported in 2014 prices. Costs were 
obtained in Danish kroner (DKK) and exchanged to € 
using the average 2014 exchange rate (1€=7.4547 DKK). 
All healthcare service use and costs are reported as means 
and standard errors and where descriptive statistics are 
presented, differences between intervention and control 
group means are reported as raw differences and, to allow 
for future meta-analysis, as standardised differences (the 
raw difference between group means, divided by the SD 
of the total sample) presented as a percentage.
Effectiveness
Information of mortalities were obtained from the Danish 
Register of Causes of Death,38 which contain mortality 
statistics on all deaths in Denmark. Utility scores stem from 
the EQ5D-3L health-related quality-of-life questionnaire 
with Danish societal weights.39 QALYs were calculated by 
linear interpolation of utility scores. The health-related 
quality-of-life items and relevant demographic data were 
collected at baseline by help from the patients’ general 
practitioners who distributed the questionnaires to all 
patients but with a prepaid return envelope to the trial 
administration office. At follow-up, a questionnaire 
consisting of the health-related quality-of-life items were 
sent from the trial administration office to the patients’ 
home addresses with a prepaid return envelope.
ANALYSIS
Statistical analyses were all performed in STATA V.12.1 
except the probabilistic sensitivity analysis that was devel-
oped in Microsoft Excel 2010.
Missing data
A total of 1225 patients were randomised in the study 
(578 patients in the telehealthcare group and 647 in the 
control group). At baseline, missing data for the EQ5D 
summary score were present for 8% of the participants 
(48 in the telehealthcare group; 53 in the control group). 
One hundred and three patients died during the trial 
period (8%; 50 in telehealthcare group; 53 in control 
group) and they were assigned an EQ5D summary score 
of 0 at follow-up that were used in the QALY calculation.40 
In addition, 27% had missing data on the EQ5D summary 
score at follow-up (199 in the telehealthcare group; 133 
in the control group) either due to non-response or to 
incomplete registration of EQ5D questionnaire items. 
Twelve percent had missing values on rehabilitation costs 
(79 in the telehealthcare group; 73 in the control group). 
Complete data for both total costs (ie, all cost categories), 
baseline EQ5D score and EQ5D score at follow-up were 
available for 751 patients (61%; 325 in telehealthcare 
group; 426 in control group).
Current good practise for trial-based economic eval-
uation recommends that analyses should account for 
missing data by imputation, especially when there is a 
large amount of missing data.41 The applied imputa-
tion procedure followed the principles recommended 
by Faria et al.42 Missing data were assumed missing at 
random (MAR), which can be a plausible assumption if a 
wide range of variables, and variables that are predictive 
of missingness, are included in the imputation model.43 
Therefore, missing data on EQ5D scores, rehabilitation 
costs and baseline characteristics were imputed using the 
mi impute chained command in STATA12.1 and 30 complete 
datasets were created. Continuous variables were imputed 
by predictive mean matching and categorical variables by 
multinomial logistic or logistic regression. Imputation 
models included outcome variables, predictors for the 
outcomes at both time points and predictors for missing 
observations in the individual variables. The imputation 
models were estimated separately by treatment group and 
included the clustering variable, measures of health-re-
lated quality-of-life (EQ5D scores), costs at baseline or at 
12 months follow-up (in the categories presented in table 
4), measures of disease status (forced expiratory volume 
in one second (FEV1%), forced vital capacity (FVC%), 
diastolic and systolic blood pressure), smoking status, 
presence of comorbidities (diabetes, cancer, cardiovas-
cular disease, mental illness or musculoskeletal disorders) 
and sociodemographic variables (age, gender, marital 
status, education and employment status).
Cost-effectiveness analysis
The cost-effectiveness analysis followed an inten-
tion-to-treat principle. The statistical analysis applied 
multilevel modelling for continuous variables that rely 
on near-normality,44 which has been suggested as an 
analysis strategy for cost-effectiveness research of clus-
ter-randomised trials.45 To allow for different sets of 
covariates, estimation of incremental total costs and 
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incremental QALYs gained was based on two separate 
linear mixed effects models; one for total costs and one 
for QALYs. Total costs were controlled for treatment 
arm, baseline EQ5D score, baseline costs (total costs 12 
months prior to randomisation), age, baseline FEV1%, 
presence of musculoskeletal disease (a significant cost 
driver in municipality districts) and clustering. QALYs 
gained were controlled for treatment group, baseline 
EQ5D score, age, gender, baseline FEV1%, marital 
status, presence of diabetes, presence of cancer and 
clustering. These estimations were facilitated by the mi 
estimate: xtmixed command with robust standard errors. 
A deterministic ICER estimate was calculated using the 
treatment beta-coefficients from these two models. In 
order to explore the uncertainty surrounding cost-ef-
fectiveness, the output from the mi estimate: xtmixed was 
exported to Microsoft Excel 2010 along with Cholesky’s 
decomposition matrix to allow for a potential correla-
tion between all the parameters in the analyses models. 
By redrawing new parameter estimates from the esti-
mated treatment effect with its SE, 5000 simulations 
were calculated to obtain new estimates of incremental 
QALYs and incremental total costs which were used to 
construct cost-effectiveness acceptability curves.
Table 2 Baseline characteristics
All 1225 participants at baseline
Telehealthcare Usual care Difference
n=578 n=647 Raw
Age (years)* 69.55 (9.36) 70.33 (9.11) −0.78
Men (%)* 48.27 (n=279) 43.74 (n=283) 4.53
Marital status (%)
Married/in a relationship 55.88 (n=323) 54.25 (n=351) 1.63
Single 20.42 (n=118) 22.10 (n=143) −1.68
Widow/widower 16.78 (n=97) 16.54 (n=107) 0.24
Missing (%) 6.92 (n=40) 7.11 (n=46) −0.19
Smoking status (%)
Non-smokers 59.34 (n=343) 63.06 (n=408) −3.72
Smokers 33.91 (n=196) 29.21 (n=189) 4.70
Missing (%) 6.75 (n=39) 7.73 (n=50) −0.98
Duration of COPD (years) 7.80 (6.23) 7.70 (5.79) 0.10
Missing (%) 14.01 (n=81) 15.14 (n=98) −1.13
FEV1 (%) 47.70 (18.05) 48.37 (18.94) −0.67
Missing (%) 18.51 (n=107) 19.78 (n=128) −1.27
FVC(%) 70.38 (20.02) 74.34 (22.33) −3.96
Missing (%) 34.43 (n=199) 39.41 (n=255) −4.98
Comorbidities (%)
Diabetes 10.21 (n=59) 9.89 (n=64) 0.32
Coronary heart disease 32.70 (n=189) 31.84 (n=206) 0.86
Mental health problem 4.84 (n=28) 4.79 (n=31) 0.05
Musculoskeletal disorder 24.91 (n=144) 29.37 (n=190) −4.46
Cancer 6.06 (n=35) 4.79 (n=31) 1.27
Missing (%) 8.13 (n=47) 7.88 (n=51) 0.25
Baseline total costs (€)† 6492 (14 150) 4900 (7149) 1.592
Missing (%) 13.66 (n=79) 11.28 (n=73) 2.38
Baseline EQ5D 0.706 (0.202) 0.716 (0.185) −0.01
Missing (%) 8.30 (n=48) 8.19 (n=53) 0.11
Data are mean (SD) or proportion (number of patients).
*Variable has no missing values.
†Baseline total costs are missing for three cost categories (help and care at home, community or district nurse and rehabilitation, see table 4) 
in four municipality districts.
COPD, chronic obstructive pulmonary disease; FEV1(%), forced expiratory volume in one second of predicted normal; FVC(%), forced vital 
capacity.
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Sensitivity analysis 1: all-cause hospital contacts
In the base-case analysis, we have sought to limit hospital 
contacts to COPD-specific contacts because the hypoth-
esis were that telehealthcare could prevent a proportion 
of admissions and emergency ward visits associated with 
exacerbations and make most COPD-specific outpatient 
control visits redundant. However, it became apparent 
that the included patients suffer from a variety of diseases 
concomitant with COPD (see table 2). As part of the inter-
vention, it is therefore plausible that a more integrated 
care and monitoring approach assisted by the telehealth-
care technology could also prevent some hospital contacts 
due to comorbidities. Some of the measurements facili-
tated by the Telekits could be indicative of cardiovascular 
disease and especially chronic heart failure. The effect on 
incremental costs of including all hospital contacts was 
therefore explored.
Sensitivity analysis 2: reduced procurement prices and 
larger scale
Potential discounts on procurement prices could be 
achieved when contemplating to implement technol-
ogies on a larger scale and increased capacity of the 
telehealthcare solution could also drastically reduce 
intervention cost, thereby affecting the cost-effective-
ness conclusion. Therefore, an effect of a 30% discount 
on Telekit equipment, installation, support and main-
tenance was explored. Thirty percent is an estimate 
stemming from experiences with negotiating procure-
ment prices subject to large-scale implementation of 
telehealthcare in the Danish healthcare sector.46 In 
addition, suppliers have stated that the costs of mainte-
nance (IT infrastructure and applications) and support 
costs does not depend on the number of patients 
included, but the complexity of the hardware and soft-
ware configuration. The effects of making these costs 
negligible due to very large-scale implementation were 
therefore also explored.
Sensitivity analysis 3: reduced monitoring time
Municipality healthcare personnel had a steep learning 
curve for their new monitoring tasks and the patients’ 
need for monitoring was uncertain at the outset. This 
resulted in approximately 5 min of average monitoring 
time per patient per week in the trial. After 12 months, 
personnel had become more efficient at monitoring 
and responding to vital values, so a new average target 
Table 3 Service use at 12 months across treatment groups and applied unit costs
Service use
Mean (SE) contacts
Between-group 
difference Unit Unit cost
Telehealthcare 
(n=578)
Usual care 
(n=647) Raw
Standardised 
(%)*
Hospital contacts
  Admissions 0.5 (0.05) 0.45 (0.49) 0.046 3.70 Per 
contact
DRG value of contact28
  Inpatient bed days 2.69 (0.31) 2.60 (0.31) 0.09 1.18 Per 
contact
Included in DRG value of 
contact28
  Outpatient/emergency 
department visits
0.87 (0.08) 0.74 (0.07) 0.13 7.16 Per 
contact
DRG value of contact28
Primary care contacts
  General practitioner 10.72 (0.35) 9.92 (0.33) 0.80 9.35 Per 
contact
Tariffs from collective 
agreement31
Municipality care (time spent)
  Help and care at 
home
2137.32 (275.17) 1614.09 (207.76) 523.24 8.79 Per 
hour
Average hourly cost across 
municipalities (€57)
  Community or district 
nurse
607.29 (100.95) 438.59 (73.00) 168.69 7.86 Per 
hour
Average hourly cost across 
municipalities (€75)
  Rehabilitation† 77.75 (14.34) 53.00 (13.21) 24.75 7.77 Per 
hour
Average hourly cost across 
municipalities (€75)
Medicines
  No. of antibiotics 2.41 (0.13) 1.89 (0.11) 0.52 17.28 Various Pharmacy consumer 
price33
  No. of R03 ATC codes 
(COPD medicine)
25.08 (0.68) 23.92 (0.65) 1.16 7.08 Various Pharmacy consumer 
price33
*Standardised difference: difference between randomisation group averages divided by the SD of the total sample.
†Incomplete register-data. Data unavailable for four municipality districts (two in the control group and two in the intervention group, 
respectively).
COPD, chronic obstructive pulmonary disease; DRG, diagnose-related group; SE, SE of the mean.
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of 2 min/week/patient (ie, 110 min annually) have 
been discussed by the North Denmark Region and the 
municipality districts47 and the effects of this target on 
cost-effectiveness is investigated.
Finally, a most optimistic scenario exploring the 
combined effect of sensitivity analyses 1, 2 and 3 was 
investigated. The effect on total costs and/or QALYs was 
explored using the same models and covariates as the 
base-case analysis.
RESULTS
Baseline characteristics of all the included patients are 
presented in table 2. Baseline characteristics are fairly 
balanced across treatment groups. The FVC(%) is lower in 
the telehealthcare group and there is an overall tendency 
for patients in the telehealthcare group to have slightly 
worse health (lower average lung function, lower average 
health-related quality of life, higher average proportion 
of comorbidities (except musculoskeletal disorders)). 
The number of smokers is higher in the intervention arm 
and baseline costs were also higher in the telehealthcare 
group.
The unadjusted healthcare service use over the trial 
period with unit costs sources is summarised in table 3. 
Average values for healthcare service use were not imputed 
(ie, values are based on non-missing cases unadjusted for 
patient case mix). Table 3 reveals that resource use is 
consistently higher in the telehealthcare group.
The unadjusted within-trial costs are summarised in 
table 4. The annual per patient healthcare service costs 
(excluding intervention costs) were higher in the tele-
healthcare group (by €836) driven primarily by higher 
costs in the municipality districts on practical help and 
home care as well as costs to community or district nurses. 
table 4 also reveals that COPD-specific hospital admis-
sions costs are roughly the same in the telehealthcare 
and usual care group. Excluding intervention costs, the 
three largest healthcare service cost drivers in telehealth-
care were COPD-specific hospital admissions (34%), costs 
associated with practical help and care in municipality 
districts (24%) and medicine (20%). By adding inter-
vention costs (also elaborated in table 4), the raw mean 
difference in annual per patient total costs between tele-
healthcare and usual care was €1540.
Table 5 presents the results of the incremental analyses. 
The base-case unadjusted average difference in QALYs 
was 0.0062 (not statistically significant) and the unad-
justed difference in total costs was €1219 per patient. 
The base-case adjusted average difference in QALYs 
was 0.0132 (not statistically significant) with an adjusted 
average difference in annual total costs of €728 per 
patient. Based on these estimates, the ICER is €55 327 
per QALY. This telehealthcare solution is therefore only 
Table 4 Average costs per patient across treatment groups at 12 months follow-up (€)
Service use
Mean (SE) costs Between-group difference
Telehealthcare (n=578) Usual care (n=647) Raw (€) Standardised (%)*
Hospital contacts
  Admissions 2756.1 (463.8) 2753.1 (458.9) 3.0 0.02
  Outpatient/emergency department visits 343.4 (24.8) 278.3 (21.5) 65.1 11.37
Primary care contacts 602.9 (17.8) 629.4 (20.3) −26.5 −5.55
Municipality care contacts
  Help and care at home 1936.7 (249.3) 1462.6 (188.2) 474.1 8.79
  Community or district nurse 733.4 (121.9) 529.7 (88.1) 203.7 7.86
  Rehabilitation† 93.4 (11.01) 61.0 (10.57) 32.4 8.56
Medicine 1610.1 (45.2) 1525.7 (37.7) 84.4 8.26
Service costs (excluding intervention costs) 8076.0 (417.6) 7239.8 (411.5) 836.2 5.76
  Project management 7.4 0 7.4 -
  Computer hardware and peripherals 200.5 0 200.5 -
  Installation 38.6 0 38.6 -
  Maintenance and support 94.6 0 94.6 -
  Training healthcare professionals 12.4 0 12.4 -
  Patient-specific training 20.6 0 20.6 -
  Monitoring vital signs 330.0 (12.76) 0 330.0 123.43
Total costs (including intervention costs) 8780.2 (417.2) 7239.8 (411.5) 1540.4 10.61
*Standardised difference: difference between randomisation group averages divided by the SD of the total sample.
†Imputed data.
SE, Standard error of the mean.
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cost-effective, if the willingness-to-pay threshold exceeds 
the ICER estimate. Figure 1 presents the cost-effectiveness 
acceptability curve (CEAC) and it can be seen that deci-
sion-makers should be willing to pay more than €55 000 
to achieve a probability of cost-effectiveness >50%.
Sensitivity analyses
Results from sensitivity analyses are also presented in 
table 5 and CEACs for all scenarios are presented in 
figure 2. In sensitivity analysis 1, all-cause hospital contacts 
were included in the analysis. Incremental total costs 
remain higher in the telehealthcare groups (€583) with 
an ICER of €44 301 per QALY. From figure 2, it can be 
seen that the willingness-to-pay threshold falls to €45 000 
per QALY to achieve a probability of cost-effectiveness 
>50%.
By reducing procurement prices and operating on a 
larger scale (sensitivity analysis 2), incremental total costs 
falls to €618 (ICER=€46 931 per QALY). The willing-
ness-to-pay threshold is €49 000 per QALY, if a probability 
of cost-effectiveness >50% should be achieved.
Sensitivity analysis 3 (reducing average per patient 
monitoring time from 5 to 2 min) would reduce incre-
mental total costs to €525 and the ICER to €39 854. The 
willingness-to-pay threshold falls to €40 000 per QALY, if a 
probability of cost-effectiveness >50% should be achieved.
In the most optimistic scenario combining the results 
from all sensitivity analyses (1+2+3), the adjusted incre-
mental costs of telehealthcare were €277 giving rise to 
an ICER of €21 068 per QALY and a willingness-to-pay 
threshold of €21 000 per QALY to achieve a probability 
of cost-effectiveness >50%.
DISCUSSION
The adjusted mean difference in QALYs was 0.0132 
(−0.0083; 0.0346) and the adjusted mean difference 
in costs were €728 (−754; 2211) leading to an ICER 
of €55 327 per QALY. This ICER is higher than any 
explicit threshold values employed by countries today, 
for example, those recommended in the UK.48 The 
cost-effectiveness conclusion is robust to changes in the 
definition of hospital contacts and reduced intervention 
costs. Only in the most optimistic scenario combining the 
effects of all sensitivity analyses, does the ICER fall below 
the UK thresholds. The telehealthcare solution is there-
fore unlikely to be cost-effective for all included patients 
with COPD.
Table 5 Incremental costs (€) and incremental QALYs at 12 months follow-up
n=1225 (telehealthcare: n=578; usual care n=647)
Between-group difference (95% CI) 
or ICER Intraclass coefficient
Base-case analysis
QALY (unadjusted mean difference)* 0.0062 (−0.0307; 0.0431) 0.007
Costs (unadjusted mean difference)* 1219 (−937; 3376) 0.014
QALY (adjusted mean difference)† 0.0132 (−0.0083; 0.0346) 0.000
Costs (€) (adjusted mean difference)‡ 728 (−754; 2211) 0.014
ICER (adjusted, € per QALY) 55 327
Sensitivity analysis 1: all-cause hospital contacts
Costs (€) (adjusted mean difference)‡ 583 (−1397; 2563) 0.005
ICER (adjusted, € per QALY) 44 301
Sensitivity analysis 2: reduced procurement prices and 
larger scale
Costs (€) (adjusted mean difference)‡ 618 (−865; 2100) 0.014
ICER (adjusted, € per QALY) 46 931
Sensitivity analysis 3: reduced monitoring time
Costs (€) (adjusted mean difference)‡ 525 (−969; 2018) 0.012
ICER (adjusted, € per QALY) 39 854
Sensitivity analysis 1+2+3: most optimistic scenario
Costs (€) (adjusted mean difference)‡ 277 (−1700; 2255) 0.014
ICER (adjusted, € per QALY) 21 068
*Linear mixed model with treatment arm as only covariate.
†Linear mixed model adjusted for treatment arm, baseline EQ5D score, age, gender, baseline FEV1%, marital status, presence of diabetes, 
presence of cancer and clustering.
‡Linear mixed model adjusted for treatment arm, baseline EQ5D score, baseline costs, age, baseline FEV1%, presence of musculoskeletal 
and clustering.
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.
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Strengths and limitations
This study is the largest trial-based cost-utility study of 
telehealthcare to patients with COPD in Denmark so far. 
A relatively broad range of cost categories from contacts 
with healthcare and social services are included and 
these contacts are all based on register data routinely 
registered in Denmark. A healthcare and social sector 
perspective was chosen that excludes transportation costs, 
time spent by patients and relatives and productivity loss 
to society. But travel distances in Denmark are relatively 
short compared with other larger countries (the longest 
distance to a university hospital is 160 km) and only 11% 
of the patients enrolled in the trial stated that they are 
employed (5% are full-time; 6% part-time).
Data on each monitoring contact was available for 21 
of the 26 municipality districts included (the remaining 
Figure 1 Cost-effectiveness acceptability curve in the base-case analysis. QALY, quality-adjusted life-year.
Figure 2 Cost-effectiveness acceptability curves for sensitivity analyses. QALY, quality-adjusted life-year. 
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5 districts has reported aggregated time spent moni-
toring each participant during the trial period). The 
median number of monitoring encounters within 
these 21 districts was 53 out of 64 planned contacts.26 
Although monitoring does not represent all facets of 
adherence and we do not have complete data for each 
individual encounter, it does suggest that participants in 
general were willing to engage with the TeleCare North 
initiative.
A limitation of the study is that single-level multiple 
imputation with clustering as a fixed effect was performed. 
Gomes et al has found that an imputation approach that 
accounts for clustering as a random effect performs 
better than single-level imputation.49 More specifically, 
Andridge have in a simulation study found that including 
clustering as a fixed effect in the imputation model could 
overestimate the uncertainty of the estimates, especially if 
the number of clusters are small and the ICC is low as in 
this case.50 However, a barrier to the adoption of multi-
level multiple imputation is that these techniques are not 
part of conventional statistical software. Furthermore, 
separate modelling of costs and effects were performed 
in the analyses of incremental QALYs and costs, which 
could be less statistically efficient than joint modelling,51 
although a multiway sensitivity analysis in a simulated 
cost-effectiveness study of bivariate multilevel models set 
to small correlations between costs and outcomes also 
perform reasonably well under the circumstances of this 
trial (eg, a small number of clusters and unequal cluster 
sizes).52
Smoking status is an important risk factor for COPD53 
and the proportion of non-smokers was lower in the 
intervention arm, which was not accounted for in the 
randomisation (eg, through minimisation). However, 
the difference in smoking status between intervention 
and control group is not statistically significant (Fisher’s 
exact test, p=0.103) and including smoking status as an 
additional covariate in the QALY and cost models have 
little impact on treatment effects (ie, incremental QALYs 
is reduced from 0.01316 to 0.01288 with smoking status 
included and incremental costs is changed from €728 to 
€705).
The way telehealthcare was implemented may have 
affected cost-effectiveness. The involved organisations 
and healthcare professionals underwent a steep learning 
curve after implementation of the telehealthcare solu-
tion, where they had to find new ways of working together 
and adapt to new work procedures. Monitoring is one 
example and personnel became more efficient at the 
end of the trial, when the needs and reactions of patients 
as well as work tasks were more familiar to municipality 
healthcare personnel. Other implementation effects such 
as how care-coordination across municipality districts, 
hospitals and general practitioners actually occurred or 
the engagement of health professionals and involved 
organisations could also have affected cost-effectiveness, 
but is hard to quantify post hoc.
Comparison with other studies
To our knowledge, three other studies have recently 
published cost-effectiveness results for telehealthcare 
involving patients with COPD and they all demonstrated 
a low probability of cost-effectiveness by the standards 
of their countries.54–56 A British study (Whole System 
Demonstrator) concludes that telehealth as a supplement 
to usual care is not likely to be cost-effective for patients 
with COPD, diabetes and chronic heart failure primarily 
due to a ‘similar’ QALY-gain and high intervention costs,54 
although this does not exclude that the COPD subgroup 
is cost-effective. The Telescot initiative for patients with 
COPD concludes that their telehealth initiative was 
associated with a non-significant QALY-gain and higher 
costs.55 A study based in Northern Ireland also concludes 
that telehealthcare is not cost-effective.56 Our findings 
are similar (non-significant QALY-gain and higher costs), 
but contrary to the UK experiences, it is not the inter-
vention costs alone that have a considerable effect on the 
cost-effectiveness of telehealthcare, but rather differences 
in community care costs and the failure to save costs on 
COPD-related hospital contacts.
Implications for clinicians and decision-makers
When interpreting small differences in effectiveness, it is 
important to be aware that results can be highly sensitive 
to between-group differences in death. Even though, it is 
standard practise to assign an EQ5D summary score of 0 
to deceased patients40 in order to calculate incremental 
QALYs, this practise could potentially have a drastic effect 
on estimated cost-effectiveness. However, in this case 
the estimated between-arm QALY difference from the 
imputed dataset and an analysis where this EQ5D scoring 
is not done, is similar (QALY difference reduced from 
0.01316 to 0.01004).
With regard to cost differences, it was suspected that 
baseline differences in costs could occur that would 
not necessarily be explained by differences in health 
or sociodemographic characteristics, for example, due 
to variations in visitation practise across municipality 
districts. The results demonstrate a big difference between 
adjusted and unadjusted costs and this raises the issue of 
the relevance of adjusting for baseline cost, if it makes 
such a large difference in a randomised study design. If 
baseline cost is removed as a covariate in the analysis of 
adjusted total costs, incremental costs rise from €728 to 
€1334. Recent guidance for trial-based cost-effectiveness 
evaluation suggest that baseline resource use should be 
collected and that the analysis of both costs and effects 
could include baseline measures of costs,41 which is also 
recommended by van Asselt et al.57 However, guidance 
is not as explicit as including baseline utility in the anal-
ysis of QALYs.58 In our opinion, the baseline difference 
in cost reported in this study underlines the importance 
of requesting information on institutional context, such 
as variations in existing resource patterns, when inter-
preting cost-effectiveness research.
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Danish decision-makers has determined that if the tele-
healthcare solution in this trial proves cost-effective, it can 
serve as a national Danish standard for a technological 
platform as well as an implementation model for tele-
healthcare to this patient group.59 However, the results 
suggest that the target COPD population in this study 
may have proven to be too broad. An implication could 
be that decision-makers should await further research, 
at least into sources of heterogeneity or explanations of 
the results from this trial, for example, there was a 10% 
difference in service cost before inclusion of interven-
tion-related costs and plausible explanations could be 
that patients randomised to telehealthcare became more 
aware of their disease and hence used more resources or it 
could be that especially municipalities discovered patients 
with an unmet need for home care when telehealthcare 
was introduced. Future research planned within this 
trial would seek to tap into explanations for this differ-
ence. It is unknown whether the telehealthcare solution 
has released its full potential for cost-effectiveness. It is 
therefore important for healthcare professionals and 
decision-makers to spend time learning from the experi-
ences gained within the trial in order to investigate if any 
best practises could be implemented that would increase 
effectiveness and/or reduce cost without compromising 
safety and effectiveness.
Future studies
This study indicates that telehealthcare could poten-
tially assist in hindering some COPD-related hospital 
contacts and hospital contacts associated with other 
diseases (incremental costs were reduced by applying 
all-cause hospital contacts). It could be a coincidence 
but also due to closer collaboration between healthcare 
delivery organisations or more frequent monitoring of 
physical measurements that may also be indicative of 
other diseases. Future studies should therefore investi-
gate the link between telehealthcare, patients with COPD 
with well-defined comorbidities and hospital contacts.
Average cost-effectiveness estimates applied in this and 
other studies could in general hide important sources of 
heterogeneity. Not much is known on prognostic criteria 
(eg, sociodemographic, geographic, lifestyle or health 
characteristics of the patients) for cost-effectiveness 
of telehealthcare to chronically ill patients, so further 
heterogeneity studies should be conducted and are also 
planned within this trial.
Telehealthcare is a complex intervention involving a 
broad class of technologies and organisational infrastruc-
tures, actions of healthcare professionals and patients. 
Experimental evaluation research has been criticised 
for being atheoretical in nature in trying to understand 
why and under what circumstances complex interven-
tions are (un)likely to lead to desired outcomes.60 In 
this study, mechanisms leading to higher health-related 
quality of life and cost in the telehealthcare group has 
largely been treated as a black-box, where patient educa-
tion, monitoring, emotional support, assisted planning, 
etc could all have an effect.13 We would recommend that 
future cost-effectiveness studies are more informed by a 
programme theory, such as the TECH model61 that was 
used in the Healthlines cost-effectiveness studies.62 63 
These studies explicitly sought to describe implemen-
tation context or account for the causation of the most 
important telehealthcare activities that were most likely to 
activate mechanisms that could lead to ‘efficient’ design 
and deployment of telehealthcare. However, context and 
mechanisms that specifically gave rise to between-arm 
differences in EQ5D in the Healthlines studies are diffi-
cult to identify, reflecting that programme theories 
are often focused on explaining trial-related aspects or 
outcomes (eg, smoking cessation or weight loss). In the 
future, context and mechanisms leading to between-arm 
differences in EQ5D and costs should receive more atten-
tion in programme theory development.
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